DUBLIN--(BUSINESS WIRE)--The "Tuberculosis - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
Summary
Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest.
Report Highlights
This Pharmaceutical and Healthcare latest pipeline guide Tuberculosis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Tuberculosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Tuberculosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 5, 11, 11, 1, 60, 37 and 4 respectively. Similarly, the Universities portfolio in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3, 6, 34 and 33 molecules, respectively.
Tuberculosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Tuberculosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Tuberculosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tuberculosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tuberculosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Tuberculosis (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tuberculosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tuberculosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Introduction
- Tuberculosis - Overview
- Tuberculosis - Therapeutics Development
- Tuberculosis - Therapeutics Assessment
- Tuberculosis - Companies Involved in Therapeutics Development
- Tuberculosis - Drug Profiles
- Tuberculosis - Dormant Projects
- Tuberculosis - Discontinued Products
- Tuberculosis - Product Development Milestones
- Appendix
Companies Mentioned
- Abera Bioscience AB
- AGILeBiotics BV
- Akshaya Bio Inc
- AN2 Therapeutics Inc
- Archivel Farma SL
- AstraZeneca Plc
- Austrianni GmbH
- BioLingus AG
- BioNTech SE
- Bioversys AG
- CanSino Biologics Inc
- Celgene Corp
- Chongqing Zhifei Biological Products Co Ltd
- Collaborations Pharmaceuticals Inc
- Consegna Pharma Inc
- Crestone Inc
- Daiichi Sankyo Co Ltd
- Demuris Ltd
- Ebelle Pharmaceuticals Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Ena Therapeutics Pty Ltd
- Enyo Pharma SA
- EpiVax Inc
- Evotec SE
- Faron Pharmaceuticals Oy
- Gamaleya Federal Research Center of Epidemiology and Microbiology
- GangaGen Inc
- GC Pharma
- GlaxoSmithKline Plc
- Globeimmune Inc
- Greffex Inc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- HanaVax Inc
- Hinova Pharmaceuticals Inc
- Hsiri Therapeutics LLC
- Immodulon Therapeutics Ltd
- Immunitor Inc
- ImmunoBiology Ltd
- Innovare R & D SA De CV
- ISR Immune System Regulation Holding AB
- Johnson & Johnson
- Kolmar Pharma Co Ltd
- L2 Diagnostics LLC
- LegoChem Biosciences Inc
- Matinas BioPharma Holdings Inc
- Merck & Co Inc
- MetalloPharm LLC
- Microbiotix Inc
- Mycosynthetix Inc
- Nearmedic Plus Ltd
- Novartis AG
- NovoBiotic Pharmaceuticals LLC
- NTxBio LLC
- Opal Biosciences Ltd
- Otsuka Holdings Co Ltd
- Pai Life Sciences Inc
- Palisades Therapeutics
- Pathens Inc
- Pfizer Inc
- Pharmapraxis
- ProCrysta Biologix Inc
- Q BioMed Inc
- Qrumpharma Inc
- Quratis Inc
- QureTech Bio AB
- Qurient Co Ltd
- Sanofi
- Sequella Inc
- Serum Institute of India Ltd
- Shanghai H&G Biotech
- Shanghai Jiatan Pharmaceutical Technology Co Ltd
- Shionogi & Co Ltd
- Spero Therapeutics Inc
- Sphaera Pharma Pte Ltd
- Takeda Pharmaceutical Co Ltd
- Target Medicals LLC
- TB-Stopper
- TenNor Therapeutics Ltd
- The Broad Institute Inc
- Theravectys SA
- TVAX Biomedical Inc
- Tydock Pharma Srl
- Vaccibody AS
- Vaxil Bio Therapeutics Ltd
- Vaxinano SE
- Vaxine Pty Ltd
- Vichem Chemie Research Ltd
- Vir Biotechnology Inc
- Zata Pharmaceuticals Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/yju5n2
